Research on the HPV vaccine has been ongoing for many years. The JCVI monitors vaccination programmes and any new evidence from research into vaccinations. Based on the new evidence, JCVI has advised that one dose provides excellent protection in young people and adults aged up to 25.
All evidence the JCVI has considered is published in its statement available at:
A number of long-term international studies have helped the JCVI to make this decision. These studies provide over 10 years’ worth of evidence to support making this change.
The evidence shows that one dose of the HPV vaccine creates antibodies that give lasting protection before people become sexually active. One dose of the HPV vaccine is more than 97% effective at protecting against the two strains of HPV that cause at least 70% of cervical cancer.
The World Health Organization’s (WHO) Strategic Advisory Group of Experts on Immunization (SAGE) has said:
“….a single-dose Human Papillomavirus (HPV) vaccine delivers solid protection against HPV, the virus that causes cervical cancer, that is comparable to 2-dose schedules. This could be a game-changer for the prevention of the disease…”
More information from WHO SAGE on the HPV vaccination programme is available at: